Aspira Women’s Health issues letter to shareholders

The Company issued the following letter to Company shareholders from CEO Nicole Sandford. “Yesterday, it was my honor to share news of an exciting development that we believe will shape Aspira Women’s Health (AWH) for many years to come. We have been selected by the Advanced Research Projects Agency for Health as an awardee of the Sprint for Women’s Health… Under this initiative, we were awarded $10 million in funding over two years to develop our multi-marker blood test to aid in the detection of endometriosis. Our test will rely on a powerful, AI-enabled algorithm that combines protein and microRNA biomarkers and patient data… The award defines a series of project milestones, the first of which we expect to meet in the fourth quarter of 2024. Upon successful acceptance of the required information related to the first milestone, Aspira will receive a payment of $2 million. The award also provides for access to a team of world-class subject matter experts and advisors to support the successful completion and commercial launch of the test before the end of the two-year contract term… Aspira was selected as one of 23 awardees from a field of over 1,700 submissions…. This is an incredible achievement and validation of Aspira’s capabilities… Now the hard work really begins! We will work with the ARPA-H team to perform an assessment and detailed analysis of execution risks.”